# Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

> **NCT01430572** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 62 (actual)

## Conditions studied

- Advanced Cancers
- Solid Tumors

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01430572
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-07
- **Primary completion:** 2020-05-12
- **Final completion:** 2020-05-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430572, "Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01430572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*